Influencing the Wnt signaling pathway in multiple myeloma

Anticancer Research

Volumn 31, Issue 2, 2011, Pages 725-730

  Kim, Young ^a   Reifenberger, Guido ^b   Lu, Desheng ^c   Endo, Tomoyuki ^d   Carson, Dennis A ^c   Gast, Sanna Marie ^a   Meschenmoser, Karoline ^a   Nowak, Michael ^a   Schmidt Wolf, Ingo G H ^a  

^a UNIVERSITY OF BONN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Multiple myeloma; Myeloma; Myeloma therapy; Review; Signal transduction; Wnt pathway

Indexed keywords

ALPHA CATENIN; ANTINEOPLASTIC AGENT; APC PROTEIN; AXIN; BETA CATENIN; BORTEZOMIB; CICLOPIROXOLAMINE; DEXAMETHASONE; DICKKOPF 1 PROTEIN; DKK1 ANTIBODY; ETACRYNIC ACID; FRIZZLED PROTEIN; GLUTATHIONE; GLUTATHIONE TRANSFERASE; GLYCOGEN SYNTHASE KINASE 3BETA; GUANINE NUCLEOTIDE BINDING PROTEIN; LENALIDOMIDE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; MELPHALAN; PLAKOGLOBIN; PREDNISONE; PROTEIN ANTIBODY; SECRETED FRIZZLED RELATED PROTEIN 2; T CELL FACTOR PROTEIN; THALIDOMIDE; UNCLASSIFIED DRUG; WNT PROTEIN;

B LYMPHOCYTE; BONE REMODELING; CELL ADHESION; CELL CYCLE PROGRESSION; CELL FATE; CELL MATURATION; CELL MOTILITY; CELL PROLIFERATION; CELL STRUCTURE; CYTOTOXICITY; DISEASE COURSE; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; HUMAN; LYMPHOMA; MULTIPLE MYELOMA; MYCOSIS; MYELOMA CELL; NEOPLASM; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION;

BETA CATENIN; HUMANS; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 79953243181     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Bensinger WI: Role of autologous and allogeneic stem cell transplantation in myeloma. Leukemia 23(3): 442-448, 2009.
2. Vesole DH, Zhang L, Flomenberg N, Greipp PR, Lazarus HM and Huff CA: ECOG Myeloma and BMT Committees: A phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97. Biol Blood Marrow Transplant 15(1): 83-89, 2009.
3. Nau KC and Lewis WD: Multiple myeloma: diagnosis and treatment. Am Fam Physician 78(7): 853-859, 2008.
4. Kristinsson SY, Landgren O and Rajkumar VS: Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates. Cancer J 15: 473-478, 2008.
5. Stewart AK, Richardson PG and San-Miguel JF: How I treat multiple myeloma in younger patients. Blood 114: 5436-5443, 2009.
6. Lin CK and Sung YC: Newly diagnosed multiple myeloma in Taiwan: the evolution of therapy, stem cell transplantation and new treatment agents. Hematol Oncol Stem Cell Ther 2(3): 385-393, 2009.
7. Tassone P, Tagliaferri P and Rossi M: Challenging the current approaches to multiple myeloma-related bone disease: from bisphosphonates to target therapy. Curr Cancer Drug Targets 9: 854-870, 2009.
8. Cadigan KM and Liu YI: Wnt signaling: complexity at the surface. J Cell Sci 119: 395-402, 2006.
9. 2+ pathways. Oncogene 18: 7860-7872, 1999. (Pubitemid 30066232)
10. You Z, Saims D and Chen S: Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-induced apoptosis. J Cell Biol 157: 429-440, 2002. (Pubitemid 34839807)
11. Qiang Y, Endo Y, Rubin JS and Rudikoff S: Wnt signaling in B- cell neoplasia. Oncogene 22: 1536-1545, 2003.
12. Dale TC: Signal transduction by the Wnt family of ligands. Biochem J 329: 209-223, 1998.
13. Sukhdeo K, Mani M and Zhang Y: Targeting the β-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci USA 104: 7516-7752, 2007.
14. Gan X, Wang J, Xi Y, Wu ZL, Li YP and Li L: Nuclear Dv1, c-Jun, β-catenin, and TCF form a complex leading to stabilization of β-catenin-TCF interaction. J Cell Biol 180: 1087-1100, 2008. (Pubitemid 351468467)
15. Amit S, Hatzubai A and Birman Y: Axin-mediated CKI phosphorylation of β-catenin at Ser 45: a molecular switch for the Wnt pathway. Genes Dev 16: 1066-1076, 2002. (Pubitemid 34507196)
16. Chen S, Guttridge DC and You Z: Wnt-signaling inhibits apoptosis by activating β-catenin/T-cell factor-mediated transcription. J Cell Biol 152: 87-96, 2001. (Pubitemid 32102439)
17. Willert K, Shibamoto S and Nusse R: Wnt-induced dephosphorylation of axin releases β-catenin from the axin complex. Genes Dev 13: 1768-1773, 1999. (Pubitemid 29353044)
18. Kikuchi A, Kishida S and Yamamoto H: Regulation of Wnt signaling by protein-protein interaction and post-translational modifications. Exp Mol Med 38: 1-10, 2006. (Pubitemid 43352428)
19. Polakis P: Wnt signaling and cancer. Genes Dev 14: 1837-185, 2000.
20. Lu D, Zhao Y and Tawatao R: Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 101: 3118-3123, 2004. (Pubitemid 38327744)
21. Steinhusen U, Badock V and Bauer A: Apoptosis-induced cleavage of β-catenin by caspase-3 results in proteolytic fragments with reduced transactivation potential. J Biol Chem 275: 16345-16353, 2000. (Pubitemid 30366951)
22. Edwards CM, Edwards JR, Lwin ST, Esparza J, Oyajobi BO, McCluskey B, Munoz S, Grubbs B and Mundy GR: Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 111(5): 2833-2842, 2008.
23. Schmidt M, Sievers E, Endo T, Lu D, Carson D and Schmidt- Wolf IGH: Targeting Wnt pathway in lymphoma and myeloma cells. Brit J Haematol 144: 796-798, 2009.
24. Oshima T, Abe M, Asano J, Hara T, Kitazoe K, Sekimoto E, Tanaka Y, Shibata H, Hashimoto T, Ozaki S, Kido S, Inoue D and Matsumoto T: Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 106(9): 3160-3165, 2005. (Pubitemid 41565914)
25. Dutta-Simmons J, Zhang Y and Gorgun G: Aurora kinase A is a target of Wnt/β-catenin involved in multiple myeloma disease progression. Blood 114: 2699-2708, 2009.
26. Qiang YW, Hu B and Chen Y: Bortezomib induces osteoblast differentiation via Wnt-independent activation of β-catenin/TCF signaling. Blood 113: 4319-4330, 2009.
27. Nuttall ME and Gimble JM: Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implications. Curr Opin Pharmacol 4: 290-294, 2004. (Pubitemid 38585315)
28. van der Horst G, van der Wert SM and Farih-Sips H: Downregulation of Wnt signaling by increased expression of Dickkopf-1 and -2 is a prerequisite for late-stage osteoblast differentiation of KS483 cells. J Bone Miner Res 20: 1867-1877, 2005.
29. Zechner D, Fujita Y and Hulsken J: β-Catenin signals regulate cell growth and the balance between progenitor cell expansion and differentiation in the nervous system. Dev Biol 258: 406-418, 2003. (Pubitemid 36686723)
30. Longo K, Kennel J and Ochocinska M: Wnt signaling protexts 3T3-L1 preadipocytes from apoptosis through induction of insulin-like growth factors. J Biol Chem 277: 38239-38244, 2002. (Pubitemid 35154678)
31. Hwang S, Ryu J and Kim I: Wnt-7a causes loss of differentiated phenotype and inhibits apoptosis of articular chondrocytes via different mechanisms. J Biol Chem 279: 26597-26604, 2004. (Pubitemid 38798816)
32. Kennel J and MacDougald O: Wnt signaling inhibits adipogenesis through β-catenin-dependent and -independent mechanisms. J Biol Chem 280: 24004-24010, 2005.
33. Glass DA, Bialek P and Ahn JD: Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Developmental Cell 8: 751-764, 2005. (Pubitemid 40585297)
34. Holmen SL, Zylstra CR and Mukherjee A: Essential role of β- catenin in postnatal bone acquisition. J Biol Chem 280: 21162-21168, 2005. (Pubitemid 40805677)
35. Jackson A, Vayssiere B and Garcia T: Gene array analysis of Wnt-regulated genes in C3H1OT1/2 cells. Bone 36: 585-598, 2005. (Pubitemid 40602252)
36. Fulciniti M, Tassone P and Hideshima T: Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114: 371-379, 2009.
37. Sato N, Yamabuki T, Takano A, Koinuma J, Aragaki M, Masuda K, Ishikawa N, Kohno N, Ito H, Miyamoto M, Nakayama H, Miyagi Y, Tsuchiya E, Kondo S, Nakamura Y and Daigo Y: Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy. Cancer Res 70(13): 5326-5336, 2010.
38. Aizawa S, Ookawa K, Kudo T, Asano J, Hayakari M and Tsuchida S: Characterization of cell death induced by ethacrynic acid in a human colon cancer cell line DLD-1 and suppression by N-acetyl-L-cysteine. Cancer Sci 94: 886-893, 2003. (Pubitemid 37406971)
39. Nagourney RA, Messenger JC, Kern DH and Weisenthal LM: Enhancement of anthracycline and alkylator cytotoxicity by ethacrynic acid in primary cultures of human tissues. Cancer Chemother Pharmacol 26: 318-322, 1990. (Pubitemid 20271532)
40. Hoffman BD, Hanauske-Abel HM, Flint A and Lalande M: A new class of reversible cell cycle inhibitors. Cytometry 12: 26-32, 1991.
41. Kim Y, Alpmann P, Blaum-Feder S, Krämer S, Endo T, Lu D, Carson D and Schmidt-Wolf IGH: Increased in vivo efficacy of lenalidomide by addition of piroctone olamine. In Vivo 25: 99-104, 2011.
42. Kim Y, Alpmann P, Blaum-Feder S, Krämer S, Endo T, Lu D, Carson D and Schmidt-Wolf IGH: In vivo efficacy of griseofulvin against multiple myeloma. Leuk Res. 2010.
43. WormBook: The Online Review of C. elegans Biology Pasadena (CA): WormBook. http://www.ncbi.nlm.nih.gov/books/NBK19669/ #A5797, 2005.